Latest Therapeutics Pipeline News

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Patrys Limited has completed its acquisition of Reliis Pty Ltd, adding a promising injectable quetiapine program to its clinical pipeline and strengthening its board with two new directors.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

Algorae Pharmaceuticals has secured a $384,466 cash refund from the Australian Taxation Office, reinforcing its financial position to advance AI-driven drug discovery programs.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

Neurizon Therapeutics has been granted a key Australian patent for its lead drug candidate NUZ-001, extending protection for treatments targeting ALS, Alzheimer's, and other neurodegenerative diseases through 2041. This milestone complements earlier US patent grants and sets the stage for upcoming clinical trials.

INOVIQ Limited has completed a $9.5 million placement to institutional investors and launched a $2 million Share Purchase Plan for existing shareholders, aiming to bolster its cancer diagnostics and therapeutics pipeline.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.